Table 1 Clinicopathologic features and the expression status of PARK2 in 46 osteosarcoma patients
From: PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway
Parameter | Case | PARK2 expression | P value | ||
|---|---|---|---|---|---|
Positive | Negative | ||||
Age (year) | <18 | 14 | 6 | 8 | 0.742 |
≥18 | 32 | 11 | 21 | ||
Sex | Male | 30 | 10 | 20 | 0.534 |
Female | 16 | 7 | 9 | ||
Histological grade | Well and moderately differentiated | 9 | 6 | 3 | 0.255 |
Poorly differentiated | 37 | 11 | 26 | ||
Tumor | T1 | 27 | 13 | 14 | 0.067 |
T2 | 19 | 4 | 16 | ||
Stage | I–II | 39 | 17 | 22 | 0.036 |
III | 7 | 0 | 7 | ||
